Results from a U.S. clinical trial testing the efficacy and safety of AstraZeneca’s COVID-19 vaccine may have included “outdated information,” American officials said early Tuesday. The Data Safety Monitoring Board notified the company and two health agencies late Monday that it was worried by the information AstraZeneca released on its trial. The board, which monitors trials and reviews data collected at regular intervals, “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” according to the National Institute of Allergy and Infectious Diseases, one of the agencies. The institute urged AstraZeneca to work with the board to review the data and ensure the release of the most accurate, up-to-date information as quickly as possible. AstraZeneca, based in England, said earlier Monday that an interim analysis of phase three trial data showed its vaccine is safe and effective. The …